Overview

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Status:
Completed

Trial end date:
2020-06-04

Target enrollment:

Participant gender:

Summary

To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept